<DOC>
	<DOCNO>NCT01138956</DOCNO>
	<brief_summary>This study design evaluate immune therapeutic response visceral leishmaniasis patient use N-acetylcysteine ( NAC ) adjuvant therapy pentavalent antimony .</brief_summary>
	<brief_title>Immune Response Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine</brief_title>
	<detailed_description>In study intend evaluate immune therapeutic response patient visceral leishmaniasis N-acetylcysteine ( NAC ) adjuvant standard treatment pentavalent antimony , compare treatment antimonial blind randomize clinical trial . Our hypothesis patient treat NAC associate pentavalent atimonial rapid change immune response , towards TH1 , clinical improvement compare patient use standard treatment</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Age 2 50 year Diagnosis visceral leishmaniasis Other acute chronic disease Use immunosuppressive drug AIDS History allergy NAC and/or pentavalent antimony</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Visceral leishmaniasis</keyword>
	<keyword>N-acetylcysteine</keyword>
	<keyword>Antimony</keyword>
	<keyword>Immune response</keyword>
</DOC>